Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren
Home
Synergy Chc Corp. Common Stock
Synergy CHC Corp. Reports Third Quarter 2025 Financial Results and its Eleventh Consecutive Quarter of Profitability
Business
Nov 13 2025
12 min read

Synergy CHC Corp. Reports Third Quarter 2025 Financial Results and its Eleventh Consecutive Quarter of Profitability

news images

WESTBROOK, Maine, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, is announcing its financial results for the three months ended September 30, 2025.

“We are pleased to report our 11th quarter of profitability and double-digit revenue growth, accompanied by over 300 basis points of gross margin expansion,” said Jack Ross, CEO of Synergy CHC Corp. “We made meaningful progress across our strategic priorities by expanding retail authorizations and distribution partnerships for our FOCUSfactor functional beverages and shots. Key partnerships with leading retailers, including Kroger and Wakefern, are strengthening our reach across North America. Additionally, we completed a $4.4 million public offering in August, providing us with added working capital to support continued growth and brand expansion. With this added flexibility, along with our retail and distribution efforts, we’re well positioned for growth in the fourth quarter and beyond, which we believe will create meaningful value for our shareholders.”

Third Quarter 2025 Financial Summary vs. Same Year-Ago Period

  • Revenue of $8.0 million vs. $7.1 million.

  • Gross margin of 70.9% vs. 67.2%.

  • Income from operations of $1.28 million vs. $1.05 million.

  • Net income of $125.3 thousand vs. $783.6 thousand.

  • Earnings per share of $0.01 vs. $0.11.

  • EBITDA, a non-GAAP financial measure, was $1.31 million vs. $1.33 million.

  • Adjusted EBITDA, a non-GAAP financial measure, was $1.52 million vs. $1.34 million.

  • Adjusted EBITDA per share, a non-GAAP financial measure, was $0.15 vs. $0.18.

Recent Business Highlights

  • Synergy recently announced multiple new retail and distribution wins for its FOCUSfactor supplements and beverages, including placements with Kroger and Wakefern, along with regional partnerships with EG America, AlaBev and Atlantic Importing. These agreements expand FOCUSfactor’s U.S. footprint across grocery, pharmacy and convenience channels.

  • On August 27, 2025, Synergy announced the completion of its $4.4 million underwritten public offering of common stock, providing additional working capital to support continued growth initiatives.

  • On September 22, 2025, Synergy appointed former Costco executive Teresa Thompson to the Board of Directors, strengthening the Company’s retail and consumer health expertise.

  • During the third quarter, the Company reduced outstanding liabilities by $3.3 million.

  • Subsequent to quarter end, Synergy announced that FOCUSfactor was named the #1 Pharmacist Recommended OTC Memory Supplement for 2025-2026 by Pharmacy Times, underscoring the brand’s category leadership and continued consumer and professional trust.

Third Quarter 2025 Financial Results

Revenue in the third quarter of 2025 was $8.0 million, up 12.4% compared to $7.1 million in the third quarter of 2024.

Gross margin in the third quarter of 2025 was 70.9% compared to 67.2% in the third quarter of 2024. The increase was largely driven by a favorable shift in product mix.

Operating expenses in the third quarter of 2025 were $4.4 million, up 17.7% compared to $3.7 million in the third quarter of 2024. The increase was primarily driven by incremental costs associated with being a public company and the added costs of launching the Company’s beverage division.

Income from operations for the third quarter of 2025 was $1.28 million, up 21.8% compared to $1.05 million in the third quarter of 2024. The increase in operating income was due to the improvement in gross margin.

Net income in the third quarter of 2025 was $125.3 thousand compared to net income of $783.6 thousand in the third quarter of 2024.

Earnings per share in the third quarter of 2025 was $0.01 compared to $0.11 in the third quarter of 2024.

EBITDA (a non-GAAP financial measure) in the third quarter of 2025 was $1.31 million compared to $1.33 million in the third quarter of 2024.

Adjusted EBITDA (a non-GAAP financial measure) in the third quarter of 2025 was $1.52 million, up 13.4% compared to $1.34 million in the third quarter of 2024.

Adjusted EBITDA per share (a non-GAAP financial measure) in the third quarter was $0.15 compared to $0.18 in the third quarter of 2024.

Balance Sheet and Cash Flow

As of September 30, 2025, Synergy had approximately $1.0 million in cash and cash equivalents, compared to $687.9 thousand in cash and cash equivalents as of December 31, 2024.

As of September 30, 2025, Synergy had a working capital surplus of $16.68 million, compared to a $1.12 million working capital deficit as of December 31, 2024.

As of September 30, 2025, Synergy had $2.1 million in inventory, compared to $1.7 million in inventory as of December 31, 2024.

Cash used in operating activities for the nine months ended September 30, 2025 was $3.21 million compared to cash used in operating activities of $1.38 million for the nine months ended September 30, 2024. The increase was primarily attributable to a reduction in the Company’s liabilities and higher inventory investment to launch its beverage division.

Non-GAAP Financial Measure Reconciliation: EBITDA and Adjusted EBITDA

To assist financial statement users in an assessment of our historical performance, the Company discloses non-GAAP financial measures in press releases and on investor conference calls and related events, as the Company believes that the non-GAAP information enhances investors' overall understanding of our financial performance, and should be read in addition to, rather than instead of, the financial statements prepared in accordance with GAAP.

Management believes EBITDA and Adjusted EBITDA provide useful information to investors by excluding certain items that may not be indicative of the Company’s core operating results and that can vary significantly between periods. EBITDA is defined as net income plus interest expense, income tax expense, depreciation and amortization. Adjusted EBITDA is calculated as EBITDA plus or minus foreign exchange gains or losses and non-cash expenses.

The following table reconciles net income to EBITDA and Adjusted EBITDA (in millions of US dollars):

 

 

 

3 Months ended September 30

 

 

2025

 

 

2024

 

 

 

 

Net income for the period

 

$0.13

 

 

$0.78

 

Adjusted for:

 

 

Interest expense, net

 

1.16

 

 

0.71

 

Amortization of intangible assets

 

0.03

 

 

0.03

 

Tax benefit

 

(0.01)

 

 

(0.19)

 

EBITDA

 

$1.31

 

 

$1.33

 

Foreign currency adjustment

 

0.02

 

 

0.01

 

Stock based compensation

 

0.19

 

 

-

 

Adjusted EBITDA

 

$1.52

 

 

$1.34

 

 

 

 

 

 

 

 

Conference Call

In conjunction with this announcement, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT on November 13, 2025, with the Company’s Chief Executive Officer, Jack Ross, and the Company’s Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy’s website. To access the call by phone, please register here and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time on the Company’s website.

About Synergy CHC Corp.

Synergy CHC Corp. develops and markets consumer health and wellness products, led by its flagship brands FOCUSfactor® and Flat Tummy®. FOCUSfactor®, a clinically studied brain health supplement and functional beverage line with a 25-year legacy, enjoys established distribution in the U.S., Canada, and the U.K. through major retailers including Costco, Walmart, Amazon, BJ's, and Walgreens, among others. The brand continues to accelerate growth, penetrating new markets both domestically and internationally, with recent retail wins across mass, grocery, pharmacy, convenience, and wholesale channels poised to drive meaningful gains in late 2025. Flat Tummy® complements Synergy's portfolio as a lifestyle brand focused on women's wellness and weight management.

Forward Looking Statements

Certain statements contained in this press release constitute "forward-looking statements," including statements regarding brand expansion and growth initiatives. These forward-looking statements represent Synergy's expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. These forward-looking statements are subject to risks, uncertainties and other factors, which are set forth in Synergy's registration statement on Form S-1, as amended, many of which are outside of Synergy's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements.

Any forward-looking statement speaks only as of the date on which it is made, and, except as required by law, Synergy does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Synergy to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in Synergy’s filings with the SEC. The risk factors and other factors noted in Synergy's filings could cause its actual results to differ materially from those contained in any forward-looking statement.

Investor Relations

Gateway Group
Cody Slach, Greg Robles
949.574.3860
SNYR@gateway-grp.com

 

Synergy CHC Corp.
Condensed Consolidated Balance Sheets

 

 

 

September 30,
2025

 

 

December 31,
2024

 

 

 

(unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

Current Assets

 

 

 

 

 

 

Cash and cash equivalents

 

$

1,006,489

 

 

$

687,920

 

Restricted cash

 

 

100,000

 

 

 

100,000

 

Accounts receivable, net

 

 

6,812,649

 

 

 

5,321,037

 

Other receivables

 

 

2,182,755

 

 

 

1,999,637

 

Loan receivable (related party)

 

 

4,407,449

 

 

 

4,375,059

 

Prepaid expenses (including related party amount of $1,050,212 and $312,966, respectively)

 

 

3,852,311

 

 

 

1,859,563

 

Inventory, net

 

 

2,145,966

 

 

 

1,716,552

 

Total Current Assets

 

 

20,507,619

 

 

 

16,059,768

 

 

 

 

 

 

 

 

 

 

Intangible assets, net

 

 

183,333

 

 

 

283,333

 

 

 

 

 

 

 

 

 

 

Total Assets

 

$

20,690,952

 

 

$

16,343,101

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Deficit

 

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

 

 

Accounts payable and accrued liabilities (including payable to shareholder of $88,770 and $88,644, respectively)

 

$

3,573,505

 

 

$

5,191,868

 

Income taxes payable

 

 

254,763

 

 

 

242,977

 

Contract liabilities

 

 

1,854

 

 

 

24,252

 

Short term loans payable, net of debt discount

 

 

-

 

 

 

7,725,272

 

Current portion of long-term notes payable, net of debt discount and debt issuance cost, shareholder

 

 

-

 

 

 

4,000,000

 

Total Current Liabilities

 

 

3,830,122

 

 

 

17,184,369

 

 

 

 

 

 

 

 

 

 

Long-term Liabilities:

 

 

 

 

 

 

 

 

Notes payable, net of debt discount, shareholder

 

 

-

 

 

 

8,333,053

 

Notes payable, net of debt discount

 

 

25,113,177

 

 

 

7,457,022

 

Total long-term liabilities

 

 

25,113,177

 

 

 

15,790,075

 

Total Liabilities

 

 

28,943,299

 

 

 

32,974,444

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders’ Deficit:

 

 

 

 

 

 

 

 

Common stock, $0.00001 par value; 300,000,000 shares authorized; 11,431,926 and 8,721,818, shares issued, respectively; 11,251,853 and 8,541,745 outstanding, respectively

 

 

114

 

 

 

87

 

Additional paid in capital

 

 

33,535,939

 

 

 

27,643,660

 

Accumulated other comprehensive loss

 

 

(35,915

)

 

 

(47,777

)

Accumulated deficit

 

 

(41,624,985

)

 

 

(44,099,813

)

Less: Treasury stock (180,073 shares) at cost

 

 

(127,500

)

 

 

(127,500

)

Total stockholders’ deficit

 

 

(8,252,347

)

 

 

(16,631,343

)

Total Liabilities and Stockholders’ Deficit

 

$

20,690,952

 

 

$

16,343,101

 

 

 

 

 

 

 

 

 

 


 

Synergy CHC Corp.
Unaudited Condensed Consolidated Statements of Income and Comprehensive Income

 

 

 

For the three months ended

 

 

For the nine months ended

 

 

 

September 30,
2025

 

 

September 30,
2024

 

 

September 30,
2025

 

 

September 30,
2024

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Product Sales

 

$

8,010,112

 

 

$

7,126,333

 

 

$

21,415,642

 

 

$

24,563,039

 

License Revenue

 

 

-

 

 

 

-

 

 

 

2,900,000

 

 

 

-

 

Total Revenue

 

 

8,010,112

 

 

 

7,126,333

 

 

 

24,315,642

 

 

 

24,563,039

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of sales

 

 

2,329,296

 

 

 

2,335,901

 

 

 

6,232,201

 

 

 

7,421,930

 

Gross profit

 

 

5,680,816

 

 

 

4,790,432

 

 

 

18,083,441

 

 

 

17,141,106

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling and marketing

 

 

2,729,767

 

 

 

2,509,440

 

 

 

8,668,249

 

 

 

9,149,303

 

General and administrative

 

 

1,637,706

 

 

 

1,196,784

 

 

 

4,463,745

 

 

 

3,449,007

 

Depreciation and amortization

 

 

33,333

 

 

 

33,333

 

 

 

100,000

 

 

 

100,000

 

Total operating expenses

 

 

4,400,806

 

 

 

3,739,557

 

 

 

13,231,994

 

 

 

12,698,310

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income from operations

 

 

1,280,010

 

 

 

1,050,875

 

 

 

4,851,447

 

 

 

4,442,796

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other (income) expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income

 

 

 

 

 

 

(252,405

)

 

 

 

 

 

 

(252,405

)

Interest income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

1,164,017

 

 

 

704,707

 

 

 

4,352,840

 

 

 

2,559,454

 

Gain on settlement of notes payable

 

 

 

 

 

 

-

 

 

 

(2,154,522

)

 

 

-

 

Remeasurement loss on translation of foreign subsidiary

 

 

1,773

 

 

 

7,279

 

 

 

10,762

 

 

 

2,166

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total other (income) expenses

 

 

1,165,790

 

 

 

459,581

 

 

 

2,209,080

 

 

 

2,309,215

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income before income taxes

 

 

114,220

 

 

 

591,294

 

 

 

2,642,367

 

 

 

2,133,581

 

Income tax benefit (expense)

 

 

11,107

 

 

 

192,299

 

 

 

(167,540

)

 

 

(114,272

)

Net income after tax

 

$

125,327

 

 

$

783,593

 

 

$

2,474,827

 

 

$

2,019,309

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income per share – basic

 

$

0.01

 

 

$

0.11

 

 

$

0.27

 

 

$

0.27

 

Net income per share – diluted

 

$

0.01

 

 

$

0.11

 

 

$

0.27

 

 

$

0.27

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

10,110,114

 

 

 

7,373,745

 

 

 

9,204,136

 

 

 

7,373,745

 

Diluted

 

 

10,111,134

 

 

 

7,373,745

 

 

 

9,204,136

 

 

 

7,373,745

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

 

125,327

 

 

 

783,593

 

 

 

2,474,827

 

 

 

2,019,309

 

Foreign currency translation adjustment

 

 

(26,077

)

 

 

(79,025

)

 

 

11,862

 

 

 

108,348

 

Comprehensive income

 

$

99,250

 

 

$

704,568

 

 

$

2,486,689

 

 

$

2,127,657

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

Synergy CHC Corp.
Unaudited Condensed Consolidated Statements of Cash Flows

 

 

 

For the nine
months ended

 

 

For the nine
months ended

 

 

 

September 30,
2025

 

 

September 30,
2024

 

Cash Flows from Operating Activities

 

 

 

 

 

 

Net income

 

$

2,474,827

 

 

$

2,019,309

 

Adjustments to reconcile net income to net cash used in operating activities:

 

 

 

 

 

 

 

 

Amortization of debt discount and debt issuance cost

 

 

1,128,795

 

 

 

47,519

 

Depreciation and amortization

 

 

100,000

 

 

 

100,000

 

Stock based compensation

 

 

19,941

 

 

 

9,224

 

Stock issued for modification of notes payable

 

 

847,062

 

 

 

-

 

Stock issued for services

 

 

127,200

 

 

 

-

 

Foreign currency transaction loss

 

 

5,655

 

 

 

23,777

 

Remeasurement loss on translation of foreign subsidiary

 

 

10,763

 

 

 

2,166

 

Non cash implied interest

 

 

-

 

 

 

4,799

 

Gain on settlement of debt

 

 

(2,154,522

)

 

 

-

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(1,491,612

)

 

 

(1,965,936

)

Other receivables

 

 

(183,118

)

 

 

-

 

Loan receivable, related party

 

 

(32,390

)

 

 

21,269

 

Inventory

 

 

(429,414

)

 

 

1,815,725

 

Prepaid expenses

 

 

(1,255,502

)

 

 

(205,975

)

Prepaid expense, related party

 

 

(737,246

)

 

 

(396,683

)

Income taxes payable

 

 

11,786

 

 

 

68,607

 

Contract liabilities

 

 

(22,398

)

 

 

(12,102

)

Accounts payable and accrued liabilities

 

 

(2,009,905

)

 

 

(3,011,384

)

Accounts payable, shareholder

 

 

380,929

 

 

 

102,206

 

Net cash used in operating activities

 

 

(3,209,149

)

 

 

(1,377,479

)

 

 

 

 

 

 

 

 

 

Cash Flows from Investing Activities

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Cash Flows from Financing Activities

 

 

 

 

 

 

 

 

Proceeds from issuing common stock

 

 

3,880,462

 

 

 

-

 

Advances from related party

 

 

135,000

 

 

 

3,395,587

 

Repayment of advances from related party

 

 

(135,000

)

 

 

(157,425

)

Proceeds from notes payable

 

 

18,996,250

 

 

 

600,000

 

Payment of loan financing fees

 

 

(2,010,953

)

 

 

-

 

Repayment of notes payable, shareholder

 

 

(10,000,000

)

 

 

(84,500

)

Repayment of notes payable

 

 

(7, 349,903

)

 

 

(2,857,690

)

Net cash provided by financing activities

 

 

3,515,856

 

 

 

895,972

 

 

 

 

 

 

 

 

 

 

Effect of exchange rate on cash, cash equivalents and restricted cash

 

 

11,862

 

 

 

108,348

 

Net increase (decrease) in cash, cash equivalents and restricted cash

 

 

318,569

 

 

 

(373,159

)

 

 

 

 

 

 

 

 

 

Cash and restricted cash, beginning of year

 

 

787,920

 

 

 

732,534

 

Cash and restricted cash, end of period

 

$

1,106,489

 

 

$

359,375

 

 

 

 

 

 

 

 

 

 

Supplemental Disclosure of Cash Flow Information:

 

 

 

 

 

 

 

 

Cash paid during the period for:

 

 

 

 

 

 

 

 

Interest

 

$

1,824,446

 

 

$

2,432,653

 

Income taxes

 

$

-

 

 

$

45,664

 

 

 

 

 

 

 

 

 

 

Supplemental Disclosure of Noncash Investing and Financing Activities:

 

 

 

 

 

 

 

 

Accounts payable converted to loan payable upon settlement

 

$

-

 

 

$

3,770,824

 

Reduction of short term related party note payable by reduction of prepaid balance

 

$

-

 

 

$

328,003

 

Issuance of common stock for loan financing

 

$

117,648

 

 

$

-

 

Issuance of pre-funded warrants for settlement of shareholder notes payable

 

$

899,993

 

 

$

-

 

Exercise of pre-funded warrants

 

$

4

 

 

$

-

 

Loan fees payable to lender

 

$

375,000

 

 

$

-